Total Payments
$331,692
2024 Payments
$31,081
Companies
32
Transactions
260
Medicare Patients
468
Medicare Billing
$57,106
Payment Breakdown by Category
Consulting$224,519 (67.7%)
Travel$45,687 (13.8%)
Research$34,638 (10.4%)
Other$22,438 (6.8%)
Food & Beverage$4,410 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $224,519 | 92 | 67.7% |
| Travel and Lodging | $45,687 | 46 | 13.8% |
| Unspecified | $34,638 | 24 | 10.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,438 | 6 | 4.4% |
| Food and Beverage | $4,410 | 88 | 1.3% |
| Honoraria | $3,000 | 2 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,500 | 1 | 0.8% |
| Grant | $2,500 | 1 | 0.8% |
Payments by Type
General
$297,054
236 transactions
Research
$34,638
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $101,344 | 46 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $32,270 | 10 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $30,821 | 26 | $0 (2024) |
| ABBVIE INC. | $24,900 | 15 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $24,032 | 23 | $0 (2023) |
| Janssen Research & Development, LLC | $22,500 | 10 | $0 (2018) |
| Medtronic Vascular, Inc. | $15,249 | 13 | $0 (2020) |
| Artivion, Inc. | $13,600 | 9 | $0 (2024) |
| W. L. Gore & Associates, Inc. | $13,075 | 20 | $0 (2024) |
| Medtronic, Inc. | $8,679 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,081 | 44 | AstraZeneca Pharmaceuticals LP ($10,100) |
| 2023 | $36,042 | 38 | AstraZeneca Pharmaceuticals LP ($18,948) |
| 2022 | $16,828 | 14 | E.R. Squibb & Sons, L.L.C. ($7,346) |
| 2021 | $8,238 | 9 | AbbVie Inc. ($3,300) |
| 2020 | $75,913 | 28 | E.R. Squibb & Sons, L.L.C. ($50,179) |
| 2019 | $26,662 | 34 | E.R. Squibb & Sons, L.L.C. ($13,355) |
| 2018 | $75,796 | 62 | Boehringer Ingelheim International GmbH ($22,491) |
| 2017 | $61,131 | 31 | Bayer HealthCare Pharmaceuticals Inc. ($14,850) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Artivion, Inc. | AMDS-Ascyrus Medical (Device) | — | Cash or cash equivalent | $500.00 | Research |
| Study: PERSEVERE • Category: Cardiovascular and vascular surgery | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 10/10/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,613.00 | General |
| 10/10/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Consulting Fee | Cash or cash equivalent | $1,245.00 | General |
| Category: HORMONE THERAPY | ||||||
| 09/25/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $421.20 | General |
| 09/23/2024 | Medtronic, Inc. | — | Food and Beverage | In-kind items and services | $8.15 | General |
| 09/20/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $56.00 | General |
| 09/20/2024 | Medtronic, Inc. | — | Food and Beverage | In-kind items and services | $40.74 | General |
| 09/20/2024 | Medtronic, Inc. | — | Food and Beverage | In-kind items and services | $38.12 | General |
| 09/20/2024 | Medtronic, Inc. | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 09/20/2024 | Medtronic, Inc. | — | Food and Beverage | In-kind items and services | $11.52 | General |
| 09/19/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $232.22 | General |
| 09/19/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $34.89 | General |
| 09/04/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $23.53 | General |
| Category: Medical Device | ||||||
| 08/08/2024 | Artivion, Inc. | AMDS-Ascyrus Medical (Device) | — | Cash or cash equivalent | $800.00 | Research |
| Study: PERSEVERE • Category: Cardiovascular and vascular surgery | ||||||
| 08/05/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $297.52 | General |
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/06/2024 | Artivion, Inc. | AMDS-Ascyrus Medical (Device) | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: PERSEVERE • Category: Cardiovascular and vascular surgery | ||||||
| 05/16/2024 | Medtronic, Inc. | LINQ II (Device) | Food and Beverage | In-kind items and services | $202.56 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 05/10/2024 | W. L. Gore & Associates, Inc. | Product in Development (Device) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Devices | ||||||
| 05/10/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| 05/09/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $219.00 | General |
| 05/09/2024 | Alnylam Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $130.91 | General |
| 05/09/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $100.62 | General |
| 05/09/2024 | Alnylam Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $100.62 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M11-352 | AbbVie, Inc. | $15,000 | 9 |
| PERSEVERE | Artivion, Inc. | $13,600 | 9 |
| Reveal LINQ Registry | Medtronic Vascular, Inc. | $2,813 | 1 |
| NN1436-4477 | Novo Nordisk AS | $1,200 | 1 |
| Believe APR002 Clinical Study | LivaNova USA, Inc. | $800.00 | 1 |
| ONWARDS Program | Novo Nordisk AS | $600.00 | 1 |
| Believe | LivaNova USA, Inc. | $400.00 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | Takeda Pharmaceuticals U.S.A., Inc. | $225.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 96 | 132 | $28,176 | $10,941 |
| 2022 | 3 | 101 | 145 | $26,094 | $12,584 |
| 2021 | 7 | 159 | 216 | $45,239 | $21,600 |
| 2020 | 4 | 112 | 131 | $27,405 | $11,982 |
Total Patients
468
Total Services
624
Medicare Billing
$57,106
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 54 | 63 | $10,599 | $4,554 | 43.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 36 | $9,860 | $3,559 | 36.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 16 | 16 | $4,248 | $1,708 | 40.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 17 | $3,469 | $1,119 | 32.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 64 | $11,904 | $5,483 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 69 | $9,930 | $5,248 | 52.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $4,260 | $1,853 | 43.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 70 | $12,835 | $6,021 | 46.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 54 | 60 | $8,660 | $4,674 | 54.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $6,500 | $3,404 | 52.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $7,455 | $3,193 | 42.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 14 | 17 | $3,870 | $1,985 | 51.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $3,542 | $1,280 | 36.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 17 | $2,377 | $1,043 | 43.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 21 | $6,775 | $3,655 | 53.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 50 | $7,000 | $3,214 | 45.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $5,930 | $2,047 | 34.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 30 | $4,045 | $1,870 | 46.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 14 | $3,655 | $1,197 | 32.7% |
About Dr. Scott Kasner, MD
Dr. Scott Kasner, MD is a Neurology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285666412.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Kasner, MD has received a total of $331,692 in payments from pharmaceutical and medical device companies, with $31,081 received in 2024. These payments were reported across 260 transactions from 32 companies. The most common payment nature is "Consulting Fee" ($224,519).
As a Medicare-enrolled provider, Kasner has provided services to 468 Medicare beneficiaries, totaling 624 services with total Medicare billing of $57,106. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Vascular Neurology
- Location Philadelphia, PA
- Active Since 07/07/2006
- Last Updated 02/13/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1285666412
Products in Payments
- LOKELMA (Drug) $25,550
- Xarelto (Drug) $24,675
- INVOKANA (Drug) $22,500
- PRADAXA (Drug) $22,491
- AMDS-Ascyrus Medical (Device) $13,600
- CARDIOFORM Septal Occluder (Device) $8,936
- ANDEXXA (Biological) $5,406
- Product in Development (Device) $4,125
- OFEV (Drug) $3,650
- BRILINTA (Drug) $3,246
- Reveal LINQ (Device) $3,049
- WINGSPAN (Device) $2,400
- TNKase (Biological) $1,840
- PRAXBIND (Drug) $1,550
- ORGOVYX (Drug) $1,245
- UBRELVY (Drug) $1,100
- Aortic Tissue Valve - Crown PRT (Device) $800.00
- LINQ II (Device) $450.85
- Perceval (Device) $400.00
- (9520) IGT Devices Undivided (Device) $51.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Philadelphia
Dr. Thomas Leist, M.d, M.D
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Daniel Kremens, M.d., J.d, M.D., J.D
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Jill Giordano Farmer, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Stephen Silberstein, M.d, M.D
Neurology — Payments: $936,801
Neurology $936,801
Amit Bar-Or
Neurology — Payments: $904,147
Neurology $904,147
Dr. Stephanie Nahas-Geiger, M.d, M.D
Neurology — Payments: $828,295
Neurology $828,295